Safety and Efficacy of Centanafadine Sustained-Release in Adults With Attention-Deficit Hyperactivity Disorder: Results of Phase 2 Studies

Safety and Efficacy of Centanafadine Sustained-Release in Adults With Attention-Deficit Hyperactivity Disorder: Results of Phase 2 Studies

Sharon B Wigal,1 Tim Wigal,1 Mary Hobart,2 Jessica J Madera,3 Ross A Baker,3 Eva Kohegyi,3 Anthony McKinney,4 Timothy E Wilens5 1AVIDA Inc., Newport Beach, California, USA; 2Otsuka Pharmaceutical Development & Commercialization, Inc., Rockville, Maryland, USA; 3Otsuka Pharmaceutical Developm...

Ful tanımlama

Detaylı Bibliyografya
Asıl Yazarlar: Wigal SB, Wigal T, Hobart M, Madera JJ, Baker RA, Kohegyi E, McKinney A, Wilens TE
Materyal Türü: Makale
Dil:English
Baskı/Yayın Bilgisi: Dove Medical Press 2020-06-01
Seri Bilgileri:Neuropsychiatric Disease and Treatment
Konular:
adhd rating scale-iv
efficacy
norepinephrine-dopamine-serotonin reuptake inhibitor
tolerability
Online Erişim:https://www.dovepress.com/safety-and-efficacy-of-centanafadine-sustained-release-in-adults-with--peer-reviewed-article-NDT

Internet

https://www.dovepress.com/safety-and-efficacy-of-centanafadine-sustained-release-in-adults-with--peer-reviewed-article-NDT

Benzer Materyaller